Earlier this month, Mark Lesselroth, CEO of BioPortUSA and David Reed, Principal of Reed Business law, had an opportunity to join Jon Wilks our partner at UK HealthGateway to discuss the topic of Brexit and how it could impact US market entry for UK based medtech firms. Given the uncertainty surrounding Brexit combined with the new, stringent requirements set forth in the MDR as outlined by the European Union, UK based medtech firms are facing some potentially daunting times, at least in their own backyard. With that in mind, we discussed the advantages of focusing more of your attention on the US market given our historic relationship and the fact that you are dealing with the largest medtech market in the world. To put things into perspective, last year the US did approximately $380 Billion dollars in sales. The next closest country was Germany at less than $28 Billion Dollars. The UK was around $7 Billion dollars.
Social Media
Latest Articles
Nov 5, 2021, 9:58 AM
Nov 2, 2021, 11:51 AM
Oct 28, 2021, 11:44 AM